MA32468B1 - Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k - Google Patents

Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k

Info

Publication number
MA32468B1
MA32468B1 MA33511A MA33511A MA32468B1 MA 32468 B1 MA32468 B1 MA 32468B1 MA 33511 A MA33511 A MA 33511A MA 33511 A MA33511 A MA 33511A MA 32468 B1 MA32468 B1 MA 32468B1
Authority
MA
Morocco
Prior art keywords
thiophene
pi3k inhibitors
thiazole derivatives
compounds
pi3k
Prior art date
Application number
MA33511A
Other languages
Arabic (ar)
English (en)
Inventor
David P Cardin
Jeffrey L Gaulin
Paul D Greenspan
Stepan Vyskocil
Tianlin Xu
Christelle C Renou
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41010579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32468(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA32468B1 publication Critical patent/MA32468B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés représentés par la formule (i) dans laquelle r1, r2, cy, y1, y2, x1, x2, et x3 sont tels que décrits dans la spécification. Ces composés, qui sont des inhibiteurs de pi3k, conviennent pour le traitement de troubles proliférants, inflammatoires ou cardiovasculaires.
MA33511A 2008-06-19 2011-01-13 Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k MA32468B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13248408P 2008-06-19 2008-06-19
PCT/US2009/003607 WO2009154741A1 (fr) 2008-06-19 2009-06-17 Dérivés de thiophène ou de thiazole et leur utilisation comme inhibiteurs de pi3k

Publications (1)

Publication Number Publication Date
MA32468B1 true MA32468B1 (fr) 2011-07-03

Family

ID=41010579

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33511A MA32468B1 (fr) 2008-06-19 2011-01-13 Derives de thiophene ou de thiazole et leur utilisation comme inhibiteurs de pi3k

Country Status (21)

Country Link
US (3) US8183240B2 (fr)
EP (1) EP2313399B1 (fr)
JP (1) JP5596026B2 (fr)
KR (1) KR20110018451A (fr)
CN (1) CN102066365A (fr)
AU (1) AU2009260782B2 (fr)
BR (1) BRPI0914223A2 (fr)
CA (1) CA2727069A1 (fr)
CL (1) CL2010001474A1 (fr)
CO (1) CO6331431A2 (fr)
CR (1) CR20110032A (fr)
EA (1) EA201170052A1 (fr)
ES (1) ES2491522T3 (fr)
GE (1) GEP20125650B (fr)
IL (1) IL210055A0 (fr)
MA (1) MA32468B1 (fr)
MX (1) MX2010014125A (fr)
NZ (1) NZ589844A (fr)
UA (1) UA106206C2 (fr)
WO (1) WO2009154741A1 (fr)
ZA (1) ZA201008875B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
BRPI0914223A2 (pt) * 2008-06-19 2019-09-24 Millennium Pharm Inc derivados de tiofeno ou tiazol e seus usos como inibidores de p13k
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8796314B2 (en) 2009-01-30 2014-08-05 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9139589B2 (en) 2009-01-30 2015-09-22 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2012021611A1 (fr) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
MA34797B1 (fr) * 2010-08-11 2014-01-02 Millennium Pharm Inc Hétéroaryles et leurs utilisations
EP2603216A4 (fr) * 2010-08-11 2013-12-18 Millennium Pharm Inc Hétéroaryles et utilisations
JP5726635B2 (ja) 2010-08-25 2015-06-03 株式会社Ｎｔｔドコモ マルチモードフロントエンド回路
WO2012051410A2 (fr) 2010-10-13 2012-04-19 Millennium Pharmaceuticals, Inc. Hétéroaryles et utilisations de ceux-ci
CN102503930B (zh) * 2011-10-28 2014-07-02 浙江大学 3,4,5,-三取代氨基噻吩类化合物及其制备和用途
JP6117235B2 (ja) 2011-12-15 2017-04-19 ノバルティス アーゲー Ｐｉ３ｋの活性または機能の阻害剤の使用
UY34539A (es) * 2011-12-23 2013-06-28 Millennium Pharm Inc Heteroarilos y usos de los mismos
EP2825889A4 (fr) 2012-03-14 2015-10-28 Salk Inst For Biological Studi Diagnostic de tumeur adénovirale
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
RU2015143437A (ru) 2013-03-15 2017-04-27 Дженентек, Инк. Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
RU2016136091A (ru) * 2014-02-14 2018-03-19 Дзе Юниверсити Оф Бритиш Коламбиа Соединения, воздействующие на днк-связывающий домен (dbd) андрогенового рецептора человека, в качестве терапевтических средств, а также способы их применения
PL3198009T3 (pl) 2014-09-24 2022-01-24 Salk Institute For Biological Studies Onkolityczne wirusy nowotworowe i sposoby zastosowania
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
JP7054527B2 (ja) 2016-02-23 2022-04-14 ソーク インスティテュート フォー バイオロジカル スタディーズ アデノウイルスの複製動態を測定するための高スループットアッセイ
WO2018111767A1 (fr) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Adénovirus synthétiques ciblant une tumeur et leurs utilisations
JP7430395B2 (ja) 2018-04-09 2024-02-13 ソーク インスティテュート フォー バイオロジカル スタディーズ 複製特質が増強された腫瘍溶解性アデノウイルス組成物
CA3144848C (fr) * 2019-06-28 2023-11-21 Pfizer Inc. Derives de 5-(thiophen-2-yl) -1h-tetrazole utilises en tant qu'inhibiteurs de bckdk utiles pour le traitement de diverses maladies
CN110759900B (zh) * 2019-10-25 2021-07-30 沈阳药科大学 噻吩类化合物的制备方法和用途
CN118496197A (zh) 2019-12-20 2024-08-16 拜耳公司 取代的噻吩甲酰胺、噻吩甲酸及其衍生物
CN113527281B (zh) * 2020-04-20 2023-12-22 昆山彭济凯丰生物科技有限公司 杂环化合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD275870A1 (de) 1988-09-27 1990-02-07 Univ Leipzig Verfahren zur herstellung von in 5-position verschiedenartig substituierten 3-aminothiophen-4-carbonitrilen
JP2008503446A (ja) 2004-05-06 2008-02-07 プレキシコン，インコーポレーテッド Ｐｄｅ４ｂ阻害剤及びその使用
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
RU2439074C2 (ru) 2006-04-26 2012-01-10 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНОЕ ТИЕНО[3,2-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРА ФОСФАТИДИЛИНОЗИТОЛ-3-КИНАЗЫ (РI3К)
WO2007129044A1 (fr) 2006-05-03 2007-11-15 Astrazeneca Ab Dérivés de thiazole et leur utilisation comme agents anti-tumoraux
JP5534811B2 (ja) * 2006-08-24 2014-07-02 アストラゼネカ アクチボラグ 増殖性疾患の治療に有用なモルホリノピリミジン誘導体
ES2399774T3 (es) * 2007-09-24 2013-04-03 Genentech, Inc. Compuestos de tiazolopirimidina inhibidores de PI3K y métodos de uso
US9029411B2 (en) * 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
BRPI0914223A2 (pt) * 2008-06-19 2019-09-24 Millennium Pharm Inc derivados de tiofeno ou tiazol e seus usos como inibidores de p13k

Also Published As

Publication number Publication date
EP2313399B1 (fr) 2014-05-28
AU2009260782A1 (en) 2009-12-23
WO2009154741A8 (fr) 2010-03-25
GEP20125650B (en) 2012-09-25
ES2491522T3 (es) 2014-09-08
CO6331431A2 (es) 2011-10-20
IL210055A0 (en) 2011-02-28
CL2010001474A1 (es) 2011-04-29
NZ589844A (en) 2012-11-30
KR20110018451A (ko) 2011-02-23
EA201170052A1 (ru) 2011-06-30
JP5596026B2 (ja) 2014-09-24
CR20110032A (es) 2011-03-14
ZA201008875B (en) 2012-02-29
US8440664B2 (en) 2013-05-14
AU2009260782B2 (en) 2014-12-11
BRPI0914223A2 (pt) 2019-09-24
CN102066365A (zh) 2011-05-18
US20130217689A1 (en) 2013-08-22
EP2313399A1 (fr) 2011-04-27
WO2009154741A1 (fr) 2009-12-23
US20120202812A1 (en) 2012-08-09
US8183240B2 (en) 2012-05-22
UA106206C2 (ru) 2014-08-11
CA2727069A1 (fr) 2009-12-23
US20100075951A1 (en) 2010-03-25
JP2011524904A (ja) 2011-09-08
MX2010014125A (es) 2011-02-24

Similar Documents

Publication Publication Date Title
MA32231B1 (fr) Composés organiques
MA31906B1 (fr) Inhibiteurs de la replication du virus de limmunodeficience humaine
MA35750B1 (fr) Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
WO2019035863A8 (fr) Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles hématologiques
MA33275B1 (fr) Inhibiteurs de la replication du virus de l'immunodeficience humaine
MA34797B1 (fr) Hétéroaryles et leurs utilisations
MA32171B1 (fr) Compose heterocyclique
EA201001647A1 (ru) Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов
MA34896B1 (fr) Inhibiteurs du virus de l'hepatite c
EA201001733A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
GEP20125650B (en) Thiophene or thiazole derivatives and use thereof as pi3k inhibitors
MA33731B1 (fr) Inhibiteurs du virus de l'hépatite c
GEP20146102B (en) Compounds and compositions as protein kinase inhibitors
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA29240B1 (fr) Derives d'indole pour le traitement d'infections virales
WO2008036652A3 (fr) Amidines servant de modulateurs d'indoléamine 2,3-dioxygénase
MA35342B1 (fr) Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase
MX2009002239A (es) Derivados de 5-(2-furil)-1,3-tiazol util como inhibidores de fosfatidilinositol 3-cinasa.
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
MA46490A1 (fr) Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
EP2331520A4 (fr) Dérivés de rosamine comme agents pour le traitement d'un cancer
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90